BRASKEM SA-CLASS A- ADR (BAK)
US1055321053 - ADR
BAK gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 85 industry peers in the Chemicals industry. BAK may be in some trouble as it scores bad on both profitability and health. BAK is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
BAK had negative earnings in the past year.
BAK had a negative operating cash flow in the past year.
In the past 5 years BAK reported 4 times negative net income.
BAK had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
BAK has a worse Return On Assets (-5.12%) than 77.65% of its industry peers.
With a Return On Equity value of -93.87%, BAK is not doing good in the industry: 91.76% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.12% | ||
| ROE | -93.87% | ||
| ROIC | N/A |
ROA(3y)2.32%
ROA(5y)1.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Operating Margin of BAK has declined.
With a Gross Margin value of 2.66%, BAK is not doing good in the industry: 88.24% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of BAK has declined.
The Profit Margin and Operating Margin are not available for BAK so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 2.66% |
OM growth 3Y-5.67%
OM growth 5Y-20.61%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.5%
GM growth 5Y-14.73%
2. Health
2.1 Basic Checks
BAK does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for BAK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of 0.99, we must say that BAK is in the distress zone and has some risk of bankruptcy.
BAK has a Altman-Z score of 0.99. This is in the lower half of the industry: BAK underperforms 74.12% of its industry peers.
A Debt/Equity ratio of 10.77 is on the high side and indicates that BAK has dependencies on debt financing.
The Debt to Equity ratio of BAK (10.77) is worse than 95.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.77 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.99 |
ROIC/WACCN/A
WACC9.03%
2.3 Liquidity
A Current Ratio of 1.54 indicates that BAK should not have too much problems paying its short term obligations.
With a Current ratio value of 1.54, BAK is not doing good in the industry: 71.76% of the companies in the same industry are doing better.
BAK has a Quick Ratio of 1.03. This is a normal value and indicates that BAK is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.03, BAK is not doing good in the industry: 63.53% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.54 | ||
| Quick Ratio | 1.03 |
3. Growth
3.1 Past
BAK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -333.36%.
Looking at the last year, BAK shows a very negative growth in Revenue. The Revenue has decreased by -31.09% in the last year.
Measured over the past years, BAK shows a quite strong growth in Revenue. The Revenue has been growing by 14.40% on average per year.
EPS 1Y (TTM)-333.36%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-119.57%
Revenue 1Y (TTM)-31.09%
Revenue growth 3Y22.64%
Revenue growth 5Y14.4%
Revenue growth Q2Q-34.31%
3.2 Future
The Earnings Per Share is expected to grow by 90.31% on average over the next years. This is a very strong growth
BAK is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -3.75% yearly.
EPS Next Y-1130.27%
EPS Next 2Y-150.91%
EPS Next 3Y54.11%
EPS Next 5Y90.31%
Revenue Next Year-28.29%
Revenue Next 2Y-12.63%
Revenue Next 3Y-6.05%
Revenue Next 5Y-3.75%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BAK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BAK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BAK indicates a slightly more expensive valuation: BAK is more expensive than 61.18% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 17.12 |
4.3 Compensation for Growth
BAK's earnings are expected to grow with 54.11% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-150.91%
EPS Next 3Y54.11%
5. Dividend
5.1 Amount
No dividends for BAK!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BRASKEM SA-CLASS A- ADR
NYSE:BAK (4/24/2024, 7:04:00 PM)
After market: 8.8 0 (0%)8.8
-0.09 (-1.01%)
Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.51B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.12% | ||
| ROE | -93.87% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 2.66% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.77 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.54 | ||
| Quick Ratio | 1.03 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-333.36%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-1130.27%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-31.09%
Revenue growth 3Y22.64%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y